Home
Clinical Trials
Partnerships
Contact Us
News
Careers
About Us
Management Team
Board of Directors
Scientific and Clinical Advisory Boards
Commercial Advisory Board
Our Focus
Infectious Disease
Oncology
Our Pipeline
Prophylactic
Therapeutic
Clinical Trials
Our Science and Technology
Investors
Press Releases
Events and Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
About Us
Management Team
Board of Directors
Scientific and Clinical Advisory Boards
Commercial Advisory Board
Our Focus
Infectious Diseases
Oncology
Our Pipeline
Prophylactic
Therapeutic
Clinical Trials
Our Science and Technology
News and Resources
News
Posters
Videos
Publications
Investors
Press Releases
Company Information
Corporate Governance
Events and Presentations
SEC Filings
Stock Information
Careers
Partnerships
Contact Us
Search our website
Media Mentions
Developing Vaccine to Prevent Birth Defects from Cytomegalovirus
September 12th, 2017
With eyes on Glaxo’s Engerix-B vaccine, VBI takes hep B candidate into phase 3
July 18th, 2017
Jeff Baxter Interviewed by Equities.com at the Small-Cap Stars Conference
January 12th, 2015
Variation Bio Garners $250K New Funding
September 12th, 2013
VBI Vaccines Pulls in $2.2M Debt Round
February 13th, 2012
VBI Acquires Epixis for VLP Vaccines Capabilities
September 15th, 2011
VBI buys Epixis, Gains CMV, Hep C Vaccines
September 15th, 2011
Variation Biotech Taps Backers for $7.8M in Debt Funding
July 19th, 2011
VBI Progressing with Vaccines That Don’t Require Refrigeration
March 24th, 2011
Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI
Sign Up Now